Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

811
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
811
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

398
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
398
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

406
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
406
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

581
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
581
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

878
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
878
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

1.0K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Copper peptide activated cascade catalysis for glucose regulation and hypoxia reversing in infected diabetic wound healing.

Materials today. Bio·2026
Same author

Rocket propulsion-inspired two-stage nitric oxide-releasing hydrogel for phase-matched therapy of diabetic wounds.

Acta biomaterialia·2026
Same author

A Novel β/ε Subunit Combination Expands the Tri-Subunit Acyl-CoA Carboxylase Repertoire in <i>Streptomyces coelicolor</i>.

Microorganisms·2026
Same author

[Recent advances in non-coding RNA-mediated PI3K/AKT/mTOR signaling pathway regulation involved in triple-negative breast cancer pathogenesis and progression].

Sheng li xue bao : [Acta physiologica Sinica]·2026
Same author

Spatial Multiple Importance Sampling for Real-Time Irradiance Probes.

IEEE transactions on visualization and computer graphics·2026
Same author

Bioremediation of Saline-Alkali Soil Using a Waste Biomass-Functional Microorganism Composite Amendment and Preliminary Multi-Crop Field Validation.

Microorganisms·2026

Related Experiment Video

Updated: Jan 2, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

603

Risk of Colorectal Cancer in Ulcerative Colitis Patients: A Systematic Review and Meta-Analysis.

Qing Zhou1, Zhao-Feng Shen1, Ben-Sheng Wu2

  • 1Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.

Gastroenterology Research and Practice
|November 30, 2019
PubMed
Summary

Ulcerative colitis (UC) patients face a higher risk of colorectal cancer (CRC). Disease extent, duration, and geographic location are key factors influencing CRC development in UC patients.

More Related Videos

Murine Appendectomy Model of Chronic Colitis Associated Colorectal Cancer by Precise Localization of Caecal Patch
08:51

Murine Appendectomy Model of Chronic Colitis Associated Colorectal Cancer by Precise Localization of Caecal Patch

Published on: August 24, 2019

10.5K
Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

1.5K

Related Experiment Videos

Last Updated: Jan 2, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

603
Murine Appendectomy Model of Chronic Colitis Associated Colorectal Cancer by Precise Localization of Caecal Patch
08:51

Murine Appendectomy Model of Chronic Colitis Associated Colorectal Cancer by Precise Localization of Caecal Patch

Published on: August 24, 2019

10.5K
Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

1.5K

Area of Science:

  • Gastroenterology
  • Oncology
  • Epidemiology

Background:

  • Patients with ulcerative colitis (UC) exhibit an elevated risk of developing colorectal cancer (CRC).
  • Understanding risk factors is crucial for early detection and management of CRC in UC patients.

Purpose of the Study:

  • To assess the risk of colorectal cancer (CRC) in ulcerative colitis (UC) patients.
  • To evaluate the influence of disease extent, disease duration, and geographic variations on CRC risk in UC.

Main Methods:

  • Systematic review and meta-analysis of studies published between 1988 and 2018.
  • Searched PubMed, scientific meetings, and bibliographies; included 58 studies with 267,566 UC patients.
  • Excluded patients with Crohn's disease, family history of CRC, or colorectal adenomatous polyps (CAP).

Main Results:

  • Extensive UC and left-sided UC were associated with a higher CRC risk compared to proctitis UC.
  • Geographic location influenced UC-associated CRC development.
  • CRC risk in Asian UC patients emerged after 10-20 years, while in North American UC patients, it increased after 30 years.

Conclusions:

  • Disease extent, disease duration, and geography are significant, independent risk factors for CRC development in UC patients.
  • These findings highlight the importance of considering these factors in CRC surveillance strategies for UC patients.